CD8A and cancer: HHLA2 can inhibit the function of CD4 and CD8 T cells, and blocking HHLA2 can enhance the proliferation and activation of T cells, which is helpful for cancer immunotherapy (Zhao et al., 2013; Rieder et al., 2021).